“Wildly Heterogeneous Genes”

 

September 16, 2013  |  

New approach subtypes cancers by shared genetic effects; a step toward personalized medicine

Cancer tumors almost never share the exact same genetic mutations, a fact that has confounded scientific efforts to better categorize cancer types and develop more targeted, effective treatments.

In a paper published in the September 15 advanced online edition of Nature Methods, researchers at the University of California, San Diego propose a new approach called network-based stratification (NBS), which identifies cancer subtypes not by the singular mutations of individual patients, but by how those mutations affect shared genetic networks or systems. 

Trey Ideker 

Trey Ideker, PhD

“Subtyping is the most basic step toward the goal of personalized medicine,” said principal investigator Trey Ideker, PhD, division chief of genetics in the UC San Diego School of Medicine and a professor in the departments of Medicine and Bioengineering at UC San Diego. “Based on patient data, patients are placed into subtypes with associated treatments. For example, one subtype of cancer is known to respond well to drug A, but not drug B. Without subtyping, every patient looks the same by definition, and you have no idea how to treat them differently.”

Recent advances in knowledge and technology have made it easier (and less expensive) to sequence individual genomes, especially in the treatment of cancer, which is fundamentally a disease of genes.

But genes are “wildly heterogeneous,” said Ideker. It is in combination, influenced by other factors, that mutated genes cause diseases like cancer. Every patient’s cancer is genetically unique, which can affect the efficacy and outcomes of clinical treatment.

“When you look at patients’ data at the level of genes, everybody looks different,” said Ideker. “But when you look at impacted biological networks and systems, groupings do appear. No genes are mutated in exactly the same place, but the mutations do appear in the same genetic pathways.”

Specifically, the scientists looked at somatic mutations – present in tumors but not healthy tissues – in data from lung, uterine and ovarian cancer patients compiled by The Cancer Genome Atlas, an on-going National Institutes of Health-funded program to gather and catalogue the genomes of thousands of cancer patients.

Ideker said the NBS approach has immediate clinical value. Genome sequencing of cancer patients is rapidly becoming a standard part of diagnosis. Clinicians can use NBS, he said, to better match treatment to cancer subtype. And by chronicling treatment outcomes, funneling those results back into the database, they can further refine and improve cancer therapies, making them as personalized as the individuals themselves. 

Co-authors are Matan Hofree, Department of Computer Science and Engineering, UCSD; John P. Shen and Hannah Carter, Department of Medicine, UCSD; and Andrew Gross, Department of Bioengineering, UCSD.

Funding for this research came, in part, from National Institutes of Health grants P41 GM103504 and P50 GM085764.

# # #

Media Contact: Scott LaFee, 619-543-6163, slafee@ucsd.edu


Related Specialties

Cancer



Media Contact

Share This Article


Related News

5/1/2018
The All of Us Research Program officially opens for enrollment Sunday, May 6. Led by the National Institutes of Health (NIH), All of Us is an unprecedented effort to gather genetic, biological, enviro ...
4/2/2018
The vast majority of genetic mutations associated with cancer occur in non-coding regions of the genome, yet it’s unclear how they may influence tumor development or growth. Researchers at University ...
3/5/2018
UC San Diego School of Medicine researchers developed a visible neural network and used it to build DCell, a virtual model of a functioning brewer’s yeast cell. To do this, they amassed all knowledge ...
10/24/2017
Analyzing samples from a prospective study, University of California San Diego School of Medicine researchers found that human exposure to glyphosate, a chemical widely found in weed killers, has incr ...



Follow Us